SPDR S&P Biotech ETF (NYSEARCA:XBI) Shares Bought by Mercer Global Advisors Inc. ADV

Mercer Global Advisors Inc. ADV grew its stake in SPDR S&P Biotech ETF (NYSEARCA:XBI) by 14.9% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 12,740 shares of the exchange traded fund’s stock after buying an additional 1,651 shares during the quarter. Mercer Global Advisors Inc. ADV’s holdings in SPDR S&P Biotech ETF were worth $1,147,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of XBI. BlueCrest Capital Management Ltd acquired a new stake in shares of SPDR S&P Biotech ETF during the 4th quarter valued at about $138,051,000. RA Capital Management L.P. purchased a new stake in shares of SPDR S&P Biotech ETF in the fourth quarter valued at approximately $110,615,000. Itau Unibanco Holding S.A. acquired a new position in shares of SPDR S&P Biotech ETF during the 4th quarter worth approximately $1,173,000. Rehmann Capital Advisory Group lifted its position in shares of SPDR S&P Biotech ETF by 7.0% during the 4th quarter. Rehmann Capital Advisory Group now owns 5,291 shares of the exchange traded fund’s stock valued at $477,000 after buying an additional 345 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC increased its holdings in SPDR S&P Biotech ETF by 106.6% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 7,155 shares of the exchange traded fund’s stock worth $644,000 after acquiring an additional 115,554 shares in the last quarter.

SPDR S&P Biotech ETF Stock Down 2.1 %

XBI opened at $76.39 on Friday. The firm’s fifty day simple moving average is $80.77 and its two-hundred day simple moving average is $89.27. SPDR S&P Biotech ETF has a 52-week low of $66.66 and a 52-week high of $105.47. The company has a market cap of $4.85 billion, a price-to-earnings ratio of 11.47 and a beta of 1.00.

SPDR S&P Biotech ETF Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.